Race Oncology |
High $1.29 |
Low $1.18 |
Trades 155 |
Turnover $303,224 |
Volume 249,053 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (14-Nov) $307,828,256 (417th) |
Close (30-Jun) $1.23 |
Volume (30-Jun) 249,053 |
Shortsold (9-Nov) 19,354 (0.01%) (577th) |
|
52w High $3.79 |
52w Low $1.40 |
P/E - |
EPS -0.06 |
New Collaboration to Understand Zantrene Cardioprotection
RAC released this announcement to the ASX on 2 March 2023, 12:33. The announcement is marked as price sensitive, and is 3 page(s) in length and 110.53kb in size.
You can view all announcements from RAC and see how they appear on a price chart on the announcements page.
At the date of this announcement, RAC was 0.000% short sold according to ASIC data. It was ranked the 629th most shorted stock on the ASX. It is now ranked as the 577th most shorted stock on the ASX with 0.010% of total shares short sold as of the latest reported data (09 November 2026).
| Other Recent Announcements from RAC | |
|---|---|
| Notification of cessation of securities - RAC | 29 June 2023, 9:54 |
| Proposed issue of securities - RAC | 29 June 2023, 9:52 |
| Initial Director's Interest Notice | 29 June 2023, 9:46 |
| New Collaboration to Understand Zantrene Cardioprotection | 2 March 2023, 12:33 |
| Appendix 4D & Half-Year Financial Statements | 27 February 2023, 16:31 |
| Results of Meeting | 21 February 2023, 10:56 |
| Appendix 3Y - Dr Daniel Tillett | 7 February 2023, 15:34 |
If you were already registered, log in here.